Compare Dominion Energy Inc (D) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dominion Energy Inc vs Davita Inc — how do they compare? Dominion Energy Inc trades at $61.61 (market cap $54.31B), while Davita Inc trades at $179.56 (market cap $11.29B). The key difference: Dominion Energy Inc is far larger — about 4.8× Davita Inc's market cap, and Dominion Energy Inc pays a 4.32% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dominion Energy Inc for 76 Days and Davita Inc for 113 Days on average.
| D | DVA | |
|---|---|---|
Market Cap | $54.31B | $11.29B |
Volume | 6,944,775 | 582,204 |
Sector | Utilities | Health |
52-Week High | $71.67 | $240.96 |
52-Week Low | $57.08 | $103.87 |
Typical Hold Time | 76 Days | 113 Days |
Enterprise Value | $108.43B | $24.01B |
Dividend Yield | 4.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dominion Energy (D) trades at $61.53, down 0.76% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with revenue growth from $14.5B in 2024 to $16.5B in 2025 and net income margin improving to 18.16%. Analyst consensus is mixed with 36% buy ratings but a $71.56 price target suggesting 16% upside. The pending merger with NextEra Energy dominates recent news coverage, creating both opportunity and regulatory uncertainty.
The stock presents a value opportunity with reasonable valuation multiples (P/E 21.37, P/S 2.96) and consistent profitability, though technical indicators suggest near-term pressure. Key risks include merger approval uncertainty, high debt levels, and interest rate sensitivity. The dividend yield of approximately 4.4% provides income support while investors await merger resolution and continued execution on data center and renewable energy investments.
DaVita (DVA) trades at $176.78, down 2.01% today, with a bearish technical signal and neutral oscillators. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $4.02 beating expectations of $3.88. Revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026, though net margins have fluctuated. Recent partnership expansion with Humana for value-based kidney care represents significant business development.
DVA presents a mixed outlook with 43% analyst buy ratings and a $235.67 price target suggesting 33% upside. However, high debt levels (65.55% debt-to-asset ratio) and regulatory risks in healthcare weigh on fundamentals. The stock's current valuation at P/E 15 and P/S 0.88 appears reasonable relative to earnings growth potential, making it attractive for value investors despite near-term bearish technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dominion Energy Inc
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.
Read more on D →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
